KLRK1 and neoplasm: This approach has been validated in various experimental models, where DNA damage inducers led to marked upregulation of MICA and improved NK cell‐mediated tumor cell elimination.[32] Chemotherapeutic agents further contribute to this process by inducing DNA damage and cellular senescence, indirectly enhancing NKG2D ligand expression and improving NK cell efficacy against tumors.[33] The combination of DNA damage inducers with NK cell immunotherapy, therefore, holds potential for innovative tumor treatment strategies with enhanced therapeutic outcomes.